Adrenal Cancer
Symptoms, Doctors, Treatments, Advances & More

Adrenal Cancer Overview

Save information for later
Sign Up

Learn About Adrenal Cancer

What is the definition of Adrenal Cancer?
Adrenal cancer is a rare form of cancer that occurs due to abnormal and uncontrolled cell growth in the adrenal glands (small glands that sit above each kidney). In most cases, the underlying cause of the condition is unknown. However, certain genetic conditions such as multiple endocrine neoplasia type 2, Li-Fraumeni syndrome, Von Hippel-Lindau syndrome, neurofibromatosis type I, and Carney complex are associated with an increased risk of developing adrenal tumors and cancer.
What are the alternative names for Adrenal Cancer?
  • Adrenal cancer
What are the different types of Adrenal Cancer?

Common conditions include: Adrenal Gland Adenoma, Pheochromocytoma

Who are the top Adrenal Cancer Local Doctors?
Elite in Adrenal Cancer
Dr. Margaret Wierman
Endocrinology
Elite in Adrenal Cancer
Dr. Margaret Wierman
Endocrinology

University Of Colorado Hospital Authority

1635 Aurora Ct, 
Aurora, CO 
720-848-2650
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Margaret Wierman is an Endocrinologist in Aurora, Colorado. Dr. Wierman is rated as an Elite provider by MediFind in the treatment of Adrenal Cancer. Her top areas of expertise are Adrenocortical Carcinoma, Pituitary Tumor, Adrenal Cancer, Hypothalamic Tumor, and Hormone Replacement Therapy (HRT).

Anand Vaidya
Elite in Adrenal Cancer
Dr. Anand Vaidya
Endocrinology
Elite in Adrenal Cancer
Dr. Anand Vaidya
Endocrinology

Brigham And Women's Hospital, Division Of Endocrinology, Diabetes And Hypertension

221 Longwood Avenue 2nd Floor Brigham And Women's At 221 Longwood Boston, 2nd Floor Brigham And Women's At 221 Longwood, 
Boston, MA 
617-732-5661
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Anand Vaidya is an Endocrinologist in Boston, Massachusetts. Dr. Vaidya is rated as an Elite provider by MediFind in the treatment of Adrenal Cancer. His top areas of expertise are Hyperaldosteronism, Adrenal Cancer, Adrenal Gland Adenoma, Gastric Bypass, and Thyroidectomy.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Adrenal Cancer
Dr. Mouhammed Habra
Endocrinology
Elite in Adrenal Cancer
Dr. Mouhammed Habra
Endocrinology

UT MD Anderson Cancer Center

1515 Holcombe Blvd, 
Houston, TX 
713-563-7600
Languages Spoken:
English
See accepted insurances

Mouhammed Habra is an Endocrinologist in Houston, Texas. Dr. Habra is rated as an Elite provider by MediFind in the treatment of Adrenal Cancer. His top areas of expertise are Adrenocortical Carcinoma, Adrenal Cancer, Thyroid Cancer, Tissue Biopsy, and Thyroidectomy.

View All Doctors
What are the latest Adrenal Cancer Clinical Trials?
A Phase II Study of Cabozantinib in Combination With Cemiplimab (Cabo-Cemiplimab) Versus Cabozantinib Alone in Adolescents and Adults With Advanced Adrenocortical Cancer
A Phase II Study of Cabozantinib in Combination With Cemiplimab (Cabo-Cemiplimab) Versus Cabozantinib Alone in Adolescents and Adults With Advanced Adrenocortical Cancer
Enrollment Status: Recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug, Biological
Study Phase: Phase 2

Summary: This phase II trial compares the effect of giving cabozantinib with or without cemiplimab in patients with adrenocortical cancer that has spread to nearby tissue or lymph nodes (locally advanced), and that cannot be removed by surgery (unresectable) or that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the b...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 1, First-in-human (FIH), Multicenter, Open-label Trial of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma (ACC) and Metastatic Castration-resistant Prostate Cancer (mCRPC)
A Phase 1, First-in-human (FIH), Multicenter, Open-label Trial of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma (ACC) and Metastatic Castration-resistant Prostate Cancer (mCRPC)
Enrollment Status: Recruiting
Publish Date: February 12, 2026
Intervention Type: Drug
Study Phase: Phase 1

Summary: This FIH study is designed to assess the safety, tolerability, and preliminary efficacy signals of DS9051b in participants with ACC and mCRPC.

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center